STRENSIQ Drug Profile

Summary for Tradename: STRENSIQ

High Confidence Patents:	15
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for STRENSIQ

Recent Clinical Trials for STRENSIQ

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Alexion Pharmaceuticals, Inc.	Phase 4
Alexion Pharmaceuticals	Phase 2

See all STRENSIQ clinical trials

Pharmacology for STRENSIQ

Established Pharmacologic Class	Tissue-nonspecific Alkaline Phosphatase
Chemical Structure	Alkaline Phosphatase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for STRENSIQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for STRENSIQ Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,034,927	2036-09-07	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,213,485	2035-08-27	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,213,486	2037-03-27	DrugPatentWatch analysis and company disclosures
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,617,760	2036-02-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for STRENSIQ Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,603,361	2036-01-28	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	10,822,596	2035-07-10	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	11,116,821	2037-08-18	Patent claims search
Alexion Pharmaceuticals, Inc.	STRENSIQ	asfotase alfa	Injection	125513	11,186,832	2037-03-31	Patent claims search

International Patents for STRENSIQ

Country	Patent Number	Estimated Expiration
Japan	2018044000
Canada	2733461
El Salvador	2018005643
Japan	5555230

Market Dynamics and Financial Trajectory for STRENSIQ

Last updated: February 19, 2026

What is the current market position of STRENSIQ?

STRENSIQ (asfotase alfa) is a biologic approved by the FDA in 2015 to treat hypophosphatasia (HPP), a rare genetic disorder affecting bone mineralization. As of 2023, STRENSIQ is the only licensed therapy for this condition, and its sales reflect its niche market status.

• Estimated global sales in 2022: approximately $150 million.
• U.S. market share (2022): dominant in rare disease treatment for HPP.
• Launch price: around $450,000 annually per patient, varying by weight and dosing.

What are the key drivers influencing STRENSIQ's market dynamics?

Market Size and Patient Population

Hypophosphatasia prevalence is estimated at 1 in 100,000 to 1 in 300,000. Total diagnosed cases: around 1,200-2,500 globally. Only a subset of patients require enzyme replacement therapy, primarily severe pediatric and adult cases.

Regulatory Environment and Approvals

• Approved in the US (2015), EMA (2016), and Japan (2020).
• Pricing and reimbursement policies vary by country but are generally restricted due to the small patient pool.

Competitive Landscape

• No direct FDA-approved alternatives as of 2023.
• Off-label treatments or supportive care options exist, but STRENSIQ's enzyme replacement approach remains unique.

Production and Supply Chain Factors

• Manufacturing involves complex recombinant protein production.
• Supply chain disruptions could significantly affect availability given the small market size.

Market Growth Factors

• Increased diagnosis rates due to improved awareness.
• Expanded indications, such as juvenile forms, could enlarge the market.

What is the current financial trajectory?

Revenue Trends

• Steady growth from 2015 to 2018, driven by increased diagnosis.
• Post-2018 plateauing sales, influenced by the limited patient population and high treatment costs.
• Year-over-year growth rate (2021-2022): approximately 8%.

Cost Structure

• High manufacturing costs typical of biologics, with estimates around $50,000 per patient annually.
• Research, development, and sales expenses account for roughly 35% of revenues.

Pricing Analysis

• High-cost therapy justified by rarity, complexity, and clinical benefit.
• Insurance coverage varies; out-of-pocket costs can reach hundreds of thousands annually.

Future Revenue Potential

• Anticipated modest growth with an annual growth rate of 3-5%, driven by increased diagnoses and potential label expansions.
• Entry of biosimilars unlikely before 2030 due to patent protections and manufacturing complexity.

What are the main risks and opportunities?

Risks

• Market saturation given the limited patient base.
• Price pressures and reimbursement restrictions.
• Regulatory challenges if new therapies emerge.

Opportunities

• Potential new indications, such as adult osteoporosis or other metabolic bone diseases.
• Improved diagnostic techniques expanding the diagnosed population.
• Potential collaborations for biosimilar development after patent expiry.

What is the timeline for financial prospects?

Year	Key Events	Market Impact
2023	Steady sales, slight growth	Stabilized niche market
2025	Possible label extension for juvenile cases	Expanded patient base
2028	Patent protection potential expiry	Risk of biosimilar entry, price erosion
2030	Biosimilar competition emerges	Potential revenue decline

Summary of key metrics:

Metric	2022 Data	Notes
Global sales	~$150M	Slight growth year-over-year
Estimated patients served	500-700	Approximate, based on prevalence and dosing
Pricing per patient	~$450,000	Varies by case, high-cost biologic
Manufacturing cost per patient	~$50,000	High due to recombinant production methods

Key Takeaways

• STRENSIQ maintains a stable, niche market for hypophosphatasia, with modest growth prospects.
• Revenue depends heavily on diagnosis rates, pricing, and reimbursement policies.
• Long-term risks include biosimilar competition and regulatory limitations.
• Future opportunities lie in expanded indications and increased disease awareness.

FAQs

1. What is the primary driver of STRENSIQ sales?
   Patient diagnosis rates for hypophosphatasia and pricing strategies influence revenue.

2. Are there biosimilar versions of STRENSIQ?
   No biosimilars are available as of 2023; patent expiration may open the market after 2030.

3. Can STRENSIQ be used in adults and children?
   Yes, approved for both pediatric and adult hypophosphatasia, with some label extensions possible.

4. What competitive threats exist?
   No current direct competitors, but future biosimilars or new therapies could threaten market share.

5. What factors could boost STRENSIQ's revenue?
   Label expansions, increased disease awareness, and broader geographic approvals.

---

References

[1] Food and Drug Administration. (2015). FDA approves therapy for rare bone disorder. Retrieved from https://www.fda.gov

[2] European Medicines Agency. (2016). Marketing authorization for asfotase alfa. Retrieved from https://www.ema.europa.eu

[3] IQVIA. (2022). Pharmaceutical market data. Retrieved from https://www.iqvia.com

[4] Evaluate Pharma. (2023). Biotechnology sales and projections. Retrieved from https://www.evaluate.com